Abstract
Abstract
Background
Mixed neuroendocrine–non-neuroendocrine neoplasm (MiNEN) is a rare malignant gastrointestinal tumor. The prognosis of patients with MiNEN is poor because of the high frequency of recurrence and metastases. We report a case of esophagogastric junction MiNEN (EGJ-MiNEN) with a long-term recurrence-free survival of 5.5 years.
Case presentation
A 58-year-old male patient underwent thoracoscopic esophagectomy for esophagogastric junction adenocarcinoma. The patient’s postoperative course was uneventful. R0 resection was achieved, and the pathological diagnosis of the surgical specimen was pT3N2M0 Stage IIIA (according to the Japanese Classification of Gastric Cancer, 4th edition). Based on the pathology results, the patient was treated with postoperative adjuvant therapy with oral S-1. The patient maintained recurrence-free survival for 5.5 years postoperatively. However, 6 years postoperatively, the patient visited our department with cachexia. Computed tomography (CT) revealed a large amount of ascites and pleural effusion. He rapidly developed a poor circulatory and respiratory status and died 16 days after admission. An autopsy revealed severe bloody ascites and pleural effusion, as well as numerous nodules on the pleura and mesentery. Immunohistochemistry of the nodules revealed positivity for chromogranin A, Synaptophysin A, neural cell adhesion molecule (NCAM or CD56), and insulinoma-associated protein 1 (INSM1). The specimen showed a mixture of adenocarcinoma and neuroendocrine cell carcinoma and was diagnosed as MiNEN. Retrospective immunostaining of the surgical specimen showed similar results, and we diagnosed the patient with recurrence of EGJ-MiNEN.
Conclusion
MiNEN has a poor prognosis; however, in some cases, long-term recurrence-free survival is achieved with radical resection and adjuvant chemotherapy.
Publisher
Springer Science and Business Media LLC
Reference16 articles.
1. Modlin IM, Shapiro MD, Kidd M, Mark K. Siegfried Oberndorfer: origins and perspectives of carcinoid tumors. Hum Pathol. 2004;35:1440–51. https://doi.org/10.1016/j.humpath.2004.09.018.
2. Veits L, Lang-Schwarz C, Volkholz H, Falkeis C, Vieth M, Schulz H. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction predominantly consisting of poorly differentiated neuroendocrine carcinoma. Endoscopy. 2013;45:E16–7.
3. José FJ, Iñaki FU, Alicia C, et al. Mixed adenoneuroendocrine carcinoma (MANEC) of the esophagogastric junction: a case report and review of the literature. Rev Esp Enferm Dig. 2017;109:160–2.
4. Paurush A, Joseph W, Sabina R, et al. Mixed adenoneuroendocrine carcinoma of the esophagogastric junction: a rare find. J Investig Med High Impact Case Rep. 2017;5
5. Yamamoto M, Ozawa S, Koyanagi K, Oguma J, Kazuno A, Ninomiya Y, et al. Mixed adenoneuroendocrine carcinoma of the esophagogastric junction: a case report. Surg Case Rep. 2018;4:56. https://doi.org/10.1186/s40792-018-0464-x.